Results: The oral morphine formulation had F 0.298 (CV 36.5%), T LAG 0.45 (CV 63.6%) h and T ABS 0.71 (CV 55%) h. A single-dose morphine 100 mcgÁkg À1 achieved a mean C MAX 10 mcgÁl À1 . Repeat 4-hourly dosing achieved mean steady-state concentration 13-18 mcgÁl À1 ; concentrations associated with good analgesia after intravenous administration. Serum concentration variability was large ranging from 5 to 55 mcgÁl À1 at steady state. Conclusions: Oral morphine 200 mcgÁkg À1 then 100 mcgÁkg À1 4 h or 150 mcgÁkg À1 6 h achieves mean concentrations associated with analgesia.
There was high serum concentration variability suggesting that respiration may be compromised in some children given these doses.
Introduction
The administration of oral morphine is an alternative option to codeine for children suffering mild to moderate postoperative pain. Following reports of codeinerelated morbidity and mortality in children after adenotonsillectomy (1,2), many pediatric and general hospitals have now removed codeine from their formularies.
Codeine is a pro-drug and exerts its analgesic effects mainly via demethylation to morphine through the cytochrome P450 isozyme CYP2D6. This isozyme is well known to be subject to a genetic polymorphism that results in variable enzyme activity, with poor concentrations of analgesia experienced by some patients and rare but potentially life-threatening adverse effects in others, due to low or high serum morphine concentrations, respectively. Regulatory agencies such as Medicines and Healthcare Products Regulatory Agency (MHRA) no longer recommend its use in children under 12 years and state that codeine should not be used for postoperative analgesia following tonsillectomy or adenoidectomy in children with obstructive sleep apnea (3) . The Food and Drug Administration (FDA), Health Canada and the European Medicines Agency (EMA) have similar restrictions on the use of codeine in children.
Current recommended doses of oral morphine (200 mcgÁkg
À1 every 4 h and 300 mcgÁkg À1 every 6 h (4), and 200 mcgÁkg À1 to 500 mcgÁkg À1 every 4 h (max 5 mg) in 2-12 years (5)) are extrapolated from small pediatric studies of the pharmacokinetics (PK) of intravenous (IV) or intramuscular morphine, or slow release morphine formulations used in oncology patients. Such inferences may be inaccurate as they ignore both the extensive biotransformation of oral morphine before it reaches the central circulation and effect sites and slower enteral absorption. Morphine exerts its analgesic effects via concentrationdependent receptor activation. There is large between-subject variability in pain experience after a standardized surgical pain model and also in the clinical effectiveness of a given serum concentration. Analgesic and adverse drug effects are dependent on serum drug concentrations (6) . Intravenous infusions of 20 mcgÁkg
À1

Áh
À1 typically result in mean serum concentrations of 16-18 mcgÁl À1 (7). However, dosing regimens used clinically often vary across age groups and are not always in accordance with known pharmacokinetics (8) . Serum morphine concentrations after the administration of an oral dose for acute pain in healthy children are not well investigated.
The objective of the present study was to investigate serum morphine concentrations attained in children given oral morphine and to suggest dosing regimens by using simulation. Simulation requires knowledge of morphine PK absorption parameters. Such information was investigated using pooled time-concentration data from both healthy children given a single oral administration at escalating doses in the perioperative setting (9) and from children given intravenous morphine (10).
Patients and methods
Data
Time-concentration profiles for children given oral morphine were available from a randomized open label, observational PK study conducted at British Columbia Children's Hospital, a tertiary care academic pediatric hospital. The study was approved by the University of British Columbia/Children's and Women's Health Centre of British Columbia Research Ethics Board (H09-03286; April 6, 2010) and written informed parental consent was obtained for healthy children aged 2-6 years, with an American Society of Anesthesiologists Physical Status of I-II, and undergoing elective surgery requiring opioid analgesia with a minimum expected hospital stay of 4 h. Blood samples at 30, 60, 90, 120, 180, and 240 min were assayed using a validated high-performance liquid chromatography-mass spectrometry (LC-MS/MS) assay (11) . Intraday coefficient of variation (CV) for assays of morphine was 6%. Interday CV for assays for morphine was 10% and the minimum concentration of detection was 0.5 mcgÁl À1 . Further methodological details are available in the previous publication (9) . In order to characterize absorption parameters (oral bioavailability, F; absorption lag time, T LAG ; absorption half-time, T ABS ), these data from children given perioperative oral morphine were pooled with those from children given intravenous morphine (n = 1059, age 23 weeks postmenstrual age -3 years) (10) . These pooled data were from two earlier published studies (12, 13) concentrations were measured after the loading dose, and at 6, 12, and 24 h after surgery. The population characteristics, procedure, and morphine assay methods in these cohort groups are described elsewhere (12) (13) (14) . Pediatric assays had a quantitation limit of 5 mcgÁl À1 . The interday precision was less than 10% and the bias was about 5%. Morphine hydrochloride and sulfate dose were converted to anhydrous morphine base equivalents using a molecular weight of 285 for morphine, 322 for morphine hydrochloride, and 759 for morphine sulfate (two morphine molecules). Pharmacokinetic parameter estimates for the intravenous morphine analysis are shown in Supplementary Data (S1). Population parameter estimates were obtained using nonlinear mixed effects models (NONMEM VII, Globomax LLC, Hanover, MD, USA) (15) . This model accounts for population parameter variability (between subjects) and residual variability (random effects) as well as parameter differences predicted by covariate (fixed) effects. The population parameter variability in model parameters was modeled by a proportional variance model. An additive and proportional term (Err) was used to characterize the residual unknown variability. These population mean parameters, between-subject variance, and residual variance were estimated using the first-order conditional interaction estimate method using ADVAN4 TRANS4. Convergence criterion was three significant digits.
Pharmacokinetics
The population parameter variability was modeled in terms of random effect (g) variables. Each of these variables is assumed to have mean 0 and a variance denoted by x 2 , which is estimated. The covariance between two elements of g (e.g., CL and V) is a measure of statistical association between these two variables. Their covariance is related to their correlation (R), i.e.,
The covariance of clearance and distribution volume variability was incorporated into the model. Each study was initially assigned an individual residual error.
(b) Covariate analysis. The parameter values were standardized for a body weight of 70 kg using an allometric model (16)
where P i is the parameter in the ith individual, W i is the weight in the ith individual, and P std is the parameter in an individual with a weight W std of 70 kg. This standardization allows comparison of child parameter estimates with those reported for adults. The PWR exponent was 0.75 for clearance, 0.25 for half-times, and 1 for distribution volumes (16) .
Covariate analysis included the Hill equation (17) for investigation of clearance changes with age:
where CL std is the population estimates for CL, standardized to a 70 kg person using allometric models; PMA is the postmenstrual age in weeks; TM 50 describes the maturation half-life of the age-related changes of CL, N is the Hill coefficient.
(c) Quality of fit. Bootstrap methods, incorporated within the Wings for NONMEM program, provided a means to evaluate parameter uncertainty. A total of 1000 replications were used to estimate parameter confidence intervals. A visual predictive check (VPC) (18), a modeling tool that estimates the concentration prediction intervals and graphically superimposes these intervals on observed concentrations after a standardized dose, was used to evaluate how well the model predicted the distribution of observed morphine concentrations. Simulation was performed using 1000 subjects with characteristics taken from studied patients. For data such as these where covariates such as dose, weight, height, and sex are different for each patient, we used a prediction-corrected VPC (PC-VPC) (19) . Observations and simulations are multiplied by the population baseline value divided by the individual-estimated baseline.
(d) Simulation. Simulation studies were performed to investigate concentration variability in children given common oral morphine regimens. Simulated children (n = 1000) were aged 1 year (10 kg . An upper dose of 5 mg was also examined for these doses. A dosing interval of 3, 4, and 6 hourly was simulated.
Adverse drug reactions
Adverse drug reactions (ADR) were assessed during the 4-h study period for children given oral morphine, and those occurring after the study period were reported by parents during a 24-h follow-up phone administered questionnaire. See Supplementary Data (S2) for study definitions of ADRs. A Data Safety Monitoring Board (DSMB) was established in accordance with Research Ethics Board protocols for monitoring of patient safety. Study progress, reports of batch serum concentrations, and any ADRs were reported regularly.
Results
Descriptive statistics
Observed serum morphine concentrations were consistently low in those given oral morphine 100 mcgÁkg , respectively, but with considerable variability among the subjects. Mean observed T MAX in those given 300 mcgÁkg À1 occurred earlier at 47.1 (CV 60%) min than in those given 200 mcgÁkg À1 ; 64.5 (CV 100%) min (Table 1) .
Adverse drug effects
During the initial 4-h study period, none of the subjects experienced excessive sedation, dysphoria, pruritus, or respiratory depression requiring intervention. One subject given 200 mcgÁkg À1 who underwent dental extractions vomited during emergence from anesthesia.
Data from the 24-h postoperative questionnaire were available in 31 children (three children were lost to follow-up). Of these, 18/31 (58%) subjects were identified as having ADRs. Ten of these 18 subjects with ADRs (56%) had received continuous IV opioid therapy after the 4-h study period that may have contributed to the ADR profile (Supplementary Data (S3) ). The majority of the children with ADRs reported by parents at 24 h were in those given 300 mcgÁkg One Latin American child given 200 mcgÁkg À1 oral morphine experienced vomiting after taking ibuprofen at home. The child was taken to the emergency room (ER) and was discharged with antiemetics to take the following day. No ADRs had been reported during the 4-h study period or prior to initial discharge. The 24-h questionnaire revealed that the child had also been sleepy although this was not documented in the ER record. On later analysis, the observed C MAX for this child was 98.4 mcgÁl À1 at 30 min, six times higher and two times earlier than the other subjects in this group (mean C MAX 16.4 (CV 140%) mcgÁl À1 , T MAX 64.5 (CV 100%) min). Serum morphine-6-glucuronide and morphine-3-glucuronide concentrations at the same time point were 14.2 mcgÁl À1 and 187.6 mcgÁl
À1
, respectively. This ADR was reported to the DSMB along with the serum concentrations when they became available. Pharmacogenomic testing was not done.
PK analysis
Pharmacokinetic parameters for the intravenous formulation were fixed (Supplementary Data (S1)). Absorption parameters for those given oral morphine are shown in Table 2 . The PC-VPC plot (Figure 2) confirms the adequacy of model predictions, showing no apparent deviations between model and data.
Simulations
Mean predicted C MAX after the first dose, C MAX at steady state and mean concentration at steady state are shown in Table 3 . A target concentration of 10-20 mcgÁl À1 is achieved using a loading dose of 200 mcgÁkg À1 followed by a maintenance dose of 100 mcgÁkg À1 4 hourly. A higher dose of 150 mcgÁkg
À1
6 hourly achieves similar steady-state concentrations, but with higher peak concentrations. Figure 3 shows the time-concentration profile for a loading dose 200 mcgÁkg À1 followed by a maintenance dose of 100 mcgÁkg À1 4 hourly given to children 1 year, 3 years, 5 years, 10 years, and 15 years. The 90% prediction interval for the 5-year-old child is also shown.
Discussion
Clinical findings from this study demonstrate preinduction oral morphine was well tolerated in a day surgery unit setting (>90% administration success rate). Single doses of 200 and 300 mcgÁkg À1 resulted in observed maximum serum concentrations (C MAX ) associated with ), but with wide variability among children. Both observed onset times and simulated time to maximum concentration (1.5 h) were similar to those reported in a systematic review of orally administered immediate release morphine in adult and children (T MAX 1.1 h) (20) .
Efforts made to establish an effective minimum analgesic serum concentration in pediatrics have not been conclusive. There are many reasons for this, including pain type and severity, maturation changes with age, individual variations in pain perceptions and different sensitivities of morphine in children of differing ages (6) .
Despite the lack of a concentration-response relationship, clinical experience indicates a target serum concentration 10-20 mcgÁl À1 that has proved effective for analgesia (7, 21 ) (24) . Minimum effective analgesic concentrations of morphine in healthy subjects may be excessive and result in lethal respiratory depression in subjects with co-morbidities. Morphine concentrations of 17-30 mcgÁl À1 were found in three postoperative deaths associated with repeated dose codeine used in the setting of adenotonsillectomy (2). The high incidence of ADRs observed in this study can largely be explained by the administration of either opioid infusions or opioid-containing epidural infusions in the postoperative period. It is difficult to know the significance of the high C MAX concentration obtained in the child who re-attended for vomiting. The M3G and M6G concentrations at the same time point were similar to the rest of the group, suggesting that this was not a drug error. The child did not experience any ADRs in the 4-h study period and the serum morphine concentration was low (5.7 mcgÁl À1 ) at the 4-h time point. It is interesting to note that the child was self-identified as Latino, a group which is known to experience greater adverse effects after morphine than non-Latino children. However, these differences have not previously been explained by either an elevated morphine or metabolite concentrations or by genetic polymorphisms (25) . Simulation demonstrates both the large concentration variability predicted after oral morphine and one contributing cause. Clearance, expressed as per kilogram decreases with increasing age in children and this is reflected in the higher observed concentrations in older children (Table 3) . This is why the upper dose is limited to 5 mg by some authorities (5). We suggest a dosing regimen of 200 mcgÁkg À1 followed by 100 mcgÁkg À1 4 hourly. Simulation suggests that acceptable mean concentrations are below 20 mcgÁl À1 . A higher dose of 150 mcgÁkg À1 6 hourly achieves similar steady-state concentrations, but with higher peak values. One concern is that there is considerable PK variability and some children will suffer respiratory depression due to high serum concentrations. There is also pharmacodynamic variability that may lower (or increase) the minimum effective concentration and/or therapeutic index of any opioid therapy. This highlights the problem of a "One-Dose-Fits-All" approach. Some children given the regimen suggested may still suffer respiratory depression. The morphine dose prescribed will depend on the indication for use. A target concentration of approximately 10 mcgÁl À1 is achieved using morphine 100 mcgÁkg À1 6 hourly and this may be satisfactory for mild to moderate pain. Children are commonly prescribed acetaminophen with nonsteroidal anti-inflammatory drugs after tonsillectomy. Morphine used for analgesic rescue in these opioid naive children who may have obstructive sleep apnea and increased propensity to respiratory depression may be as dangerous as its prodrug codeine because PK variability is large. This PK variability reinforces the importance of using preventive multimodal analgesia to minimize opioid requirements wherever possible. Preventive analgesia is defined as analgesia that is provided by an intervention given in the perioperative period, which may be before or after incision and surgery, that reduces analgesic requirements for postoperative pain for a period longer than the duration of action for the analgesic intervention (26, 27) . Multimodal analgesia uses combinations of analgesics that act by different modes to enable a reduction in analgesic requirements of each type of medication and therefore reduce side effect profiles. A multimodal approach provides significant benefits which include reduction in pain intensity, opioid dose requirements, and opioid-related adverse events (27) (28) (29) . While simulations match observations in this study, it is possible that predictions were influenced by unaccounted factors. The anesthetic regimen was not standardized therefore the intraoperative effects of polypharmacy and potential drug interactions are unknown. Volatile anesthesia, positive pressure ventilation, and intra-abdominal surgery are known to reduce hepatorenal blood flow with subsequent effects on morphine clearance. Morphine acts at the effect site and an equilibration half-time (T 1/2 keo) of 16-23 min is reported for analgesia in adults (23, 30) . At steady state, concentrations in the effect site will be similar to those in serum, but with reduced peaks.
The majority of subjects were self-identified as Caucasian and results may not be applicable to other ethnic groups. Pharmacogenomic correlations were not done in this study and subjects' genotype for ADME genes involved in morphine biotransformation was unknown. Single nucleotide polymorphisms have been described for uridine 5 0 -diphospho-glucuronosyltransferase (UGT2B7), the enzyme responsible for glucuronide conjugation of morphine; however, their impact on clearance and serum morphine and metabolite concentrations is still unresolved (31) . Serum morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) concentrations were measured in this study and are reported elsewhere (9) . Morphine-6-glucuronide is an active metabolite but minimally contributes to central nervous opioid effects after analgesic doses of administered morphine (32) , and only contributes to respiratory depression in children with renal failure (22) . While the early evidence for individual genotype associations for analgesia and opioid adverse outcomes is promising, the large amount of conflicting data highlights a need for larger and more robust studies with appropriate population stratification (33) . Genetic factors have impact not only on pharmacokinetics (e.g., clearance) and pharmacodynamics (e.g., receptor response) but also on other factors that influence the pain response (e.g., catecholamines, inflammatory cytokines, ion channels). The impact of these multiple factors in any one individual is not fully understood (6).
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Supporting information
Additional Supporting Information may be found in the online version of this article:
Data S1. Population parameter estimates for morphine pharmacokinetics using a two-compartment model. Estimates are scaled using allometric theory (34). Clearance maturation parameters estimated using the Hill equation are also included.
Data S2. Study definitions of adverse drug reactions (ADRs) as reported by patient or observed by parent or healthcare worker.
Data S3. Adverse drug effects associated with oral morphine use, represented by number of subjects (% total subjects). No patients experienced respiratory depression or dysphoria.
